Coya Therapeutics (COYA) Competitors $5.68 -0.52 (-8.39%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$5.74 +0.06 (+1.06%) As of 08/14/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock COYA vs. KOD, ERAS, TECX, RGNX, PVLA, CMPX, MBX, ATXS, ETON, and KMDAShould you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include Kodiak Sciences (KOD), Erasca (ERAS), Tectonic Therapeutic (TECX), REGENXBIO (RGNX), Palvella Therapeutics (PVLA), Compass Therapeutics (CMPX), MBX Biosciences (MBX), Astria Therapeutics (ATXS), Eton Pharmaceuticals (ETON), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. Coya Therapeutics vs. Its Competitors Kodiak Sciences Erasca Tectonic Therapeutic REGENXBIO Palvella Therapeutics Compass Therapeutics MBX Biosciences Astria Therapeutics Eton Pharmaceuticals Kamada Kodiak Sciences (NASDAQ:KOD) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Do analysts recommend KOD or COYA? Kodiak Sciences currently has a consensus price target of $11.25, indicating a potential upside of 12.05%. Coya Therapeutics has a consensus price target of $16.50, indicating a potential upside of 190.49%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than Kodiak Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kodiak Sciences 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer KOD or COYA? In the previous week, Coya Therapeutics had 3 more articles in the media than Kodiak Sciences. MarketBeat recorded 13 mentions for Coya Therapeutics and 10 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.45 beat Coya Therapeutics' score of 0.09 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coya Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, KOD or COYA? Coya Therapeutics has higher revenue and earnings than Kodiak Sciences. Coya Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKodiak SciencesN/AN/A-$176.21M-$3.63-2.77Coya Therapeutics$3.55M26.77-$14.88M-$1.24-4.58 Is KOD or COYA more profitable? Coya Therapeutics' return on equity of -61.05% beat Kodiak Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kodiak SciencesN/A -134.87% -59.58% Coya Therapeutics N/A -61.05%-53.61% Do insiders & institutionals believe in KOD or COYA? 89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 45.9% of Kodiak Sciences shares are owned by company insiders. Comparatively, 12.0% of Coya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, KOD or COYA? Kodiak Sciences has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. SummaryCoya Therapeutics beats Kodiak Sciences on 9 of the 14 factors compared between the two stocks. Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COYA vs. The Competition Export to ExcelMetricCoya TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$103.69M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-4.5820.4930.2925.74Price / Sales26.77356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book3.368.608.826.15Net Income-$14.88M-$54.65M$3.25B$265.06M7 Day Performance-6.58%5.86%3.70%2.60%1 Month Performance-6.12%8.86%5.84%2.83%1 Year Performance13.37%13.33%29.92%25.58% Coya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COYACoya Therapeutics1.8195 of 5 stars$5.68-8.4%$16.50+190.5%+18.0%$103.69M$3.55M-4.586News CoverageEarnings ReportAnalyst ForecastKODKodiak Sciences3.3003 of 5 stars$8.09+10.7%$9.00+11.2%+293.7%$426.83MN/A-2.2390News CoverageEarnings ReportAnalyst UpgradeGap UpERASErasca2.4372 of 5 stars$1.50+7.1%$4.57+204.8%-39.4%$424.93MN/A-2.42120News CoverageEarnings ReportTECXTectonic Therapeutic2.2606 of 5 stars$22.53+6.5%$80.33+256.6%+52.4%$420.64MN/A-3.08120RGNXREGENXBIO4.241 of 5 stars$8.29-0.5%$29.00+249.8%-24.1%$415.83M$83.33M-2.67370Gap DownPVLAPalvella Therapeutics1.7307 of 5 stars$37.52+0.9%$52.22+39.2%N/A$414.97M$42.81M-3.10N/ANews CoverageCMPXCompass Therapeutics2.7315 of 5 stars$2.93+2.8%$12.67+332.3%+158.8%$405.17M$850K-7.1520Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionMBXMBX Biosciences2.5583 of 5 stars$12.03-4.1%$37.63+212.8%N/A$402.09MN/A0.0036News CoverageATXSAstria Therapeutics2.6866 of 5 stars$7.02+1.9%$29.00+313.1%-32.3%$396.14MN/A-3.7530News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionETONEton Pharmaceuticals2.3236 of 5 stars$14.73+2.4%$29.67+101.4%+311.3%$395.06M$39.01M-81.8320KMDAKamada4.5869 of 5 stars$6.85-4.7%$13.00+89.8%+37.0%$393.91M$167.24M23.62360News CoverageEarnings ReportShort Interest ↓ Related Companies and Tools Related Companies Kodiak Sciences Competitors Erasca Competitors Tectonic Therapeutic Competitors REGENXBIO Competitors Palvella Therapeutics Competitors Compass Therapeutics Competitors MBX Biosciences Competitors Astria Therapeutics Competitors Eton Pharmaceuticals Competitors Kamada Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COYA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access